ICU: SeaStar Medical Holding Corporation Price to Sales

Symbol and logo of brand SeaStar Medical Holding Corporation (ICU)

SeaStar Medical Holding develops advanced blood filtration systems to combat organ failure. The startup is currently implementing direct B2B deliveries of its devices to US intensive care units. Exclusive HDE status from the FDA protects its position in pediatric nephrology. The price-to-sales ratio on this chart helps assess the business's sales valuation, while the 2.10 value confirms the current level of market valuation.

ICU (SeaStar Medical) P/S Multiple history from 11/15/2024 to 11/16/2026

Analytical breakdowns for SeaStar Medical Holding Corp. (ICU)

- market price and analyst price targets:
Fundamental company analysis:SeaStar Medical Holding Corp ICU
Original product of SeaStar Medical Holding Corp

SeaStar Medical Holding generates steady revenue through the sale of consumables for its blood purification systems. This multiple compares the business's market value to its sales volume, reflecting the efficiency of its technology monetization. A time-series analysis of the P/S ratio helps identify whether the asset is overvalued or possesses hidden growth potential. The stability of this indicator confirms the fundamental resilience of the share price as the device network scales.

Who SeaStar Medical Holding competes with

DXCM (DexCom Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple PEN (penumbrainc.com)|NOVT - Market Cap to Revenue|Haemonetics - P/S Multiple|Price to Sales Inspire Medical Systems|PRCT: P/S Multiple|Market Cap to Revenue Ratio CNMD|PLSE (Pulse Medical) - P/S Multiple|InMode Corp (INMD) - Price-to-Revenue Coefficient|P/S Multiple PMI|Market Cap to Revenue Surmodics, Inc. SRDX|P/S Multiple SENS (senseonics.com)|P/S Multiple NeuroPace Inc NPCE|TCMD - Price-to-Revenue Ratio|SNWV: Price-to-Revenue Ratio|Outset Medical Corp (OM) - Price-to-Revenue Ratio|SmartVest - Market Capitalization-to-Revenue Ratio|LNSR (LENSAR Inc) - P/S Multiple|Price to Sales AVITA Medical Inc. RCEL|Price-to-Revenue Ratio Profound Medical (PROF)|Baird Medical Corp (BDMD) - Price-to-Revenue Multiple|EDAP TMS SA - Market Cap to Revenue|P/S Multiple Bovie Medical APYX|IceCure Medical Ltd. - P/S Multiple|Price-to-Revenue Coefficient Pulmonx LUNG|TELA Bio (TELA) - Price-to-Revenue Ratio|Price-to-Sales Ratio CTSO (CytoSorbents Corp.)|Price-to-Revenue Ratio sensushealthcare.com|Market Cap to Revenue Zynex, Inc. (ZYXI)|P/S Multiple ECOR|RBOT - Price to Sales|Price-to-Revenue Ratio inspira-technologies.com IINN|IRIX: Market Cap to Revenue Ratio|INBS: Market Cap to Revenue|beyondair.net - Market Cap to Sales Volume|Profusa Inc (PFSA) - Price-to-Revenue Ratio|SSKN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio GlucoTrack|P/S Multiple NanoVibronix Inc.|Price-to-Revenue Ratio Venus Concept (VERO)|Market Cap to Revenue Nuwellis, Inc. NUWE|P/S Multiple AEMD (Aethlon Medical, Inc.)|ASXC: Market Cap to Revenue Ratio|Avinger Inc. - P/S Multiple|Price-to-Revenue Coefficient BioSig Technologies, Inc BSGM|CUTR: P/S Multiple|Know Labs, Inc. (KNW) - P/S Multiple|Price-to-Revenue Ratio Inari Medical Inc|Market Cap to Revenue Nevro Corp (NVRO)|Market Cap to Revenue RSLS (ReShape Lifesciences, Inc.)|P/S Multiple Silk Road Medical Inc. (SILK)